ALSO NOTED: FDA: New Zyprexa sedates some;Vanderbilt outlaws rep freebies;

Mon, 04 Feb 2008 06:59:50 -0500

> Prepping for advisory panel review, FDA staff says long-lasting Zyprexa causes drowsiness. Report

> Vanderbilt Medical Center has become the latest hospital to ban gifts from drug reps as part of a new conflict-of-interest policy. Report

> European regulators gave the nod to Roche's chemotherapy drug Xeloda for use against metastatic colorectal cancer in combo with other chemo meds. Report

> U.K. doctors called on the National Health Service to share more information about its dealings with the pharmaceutical industry. Report

> Bayer CEO Werner Wenning says the company has plenty of cash to make acquisitions even after last year's buyout of German drug maker Schering. Report

> Schering-Plough got the FDA nod for its Asmanex Twisthaler asthma treatment for prevention of symptoms in children 4 to 11 years. Report

> Three more congressmen have joined the fray over Denderon's delayed prostate cancer vaccine Provenge. Report

> Following a label change, Novartis has won EU approval for its trouble diabetes drug Galvus. Report

> Biotech and emerging drug markets are big targets for venture capitalists. Report

And Finally... Could low-salt and high-veggie diets succeed where blood pressure meds fail? Report

BMS cancer med could earn $500M

Wed, 17 Oct 2007 06:59:54 -0400

Analysts are rubbing their hands over the FDA's approval of Ixempra, a Bristol-Myers Squibb breast cancer treatment, predicting $500 million in annual sales by 2010. The drug got the agency's nod as a stand-alone treatment for patients who've failed other chemotherapy and for use in tandem with Roche's Xeloda in patients whose cancer has spread. A treatment course of Ixempra is expected to cost $18,000 to $23,000.

- see the BMS release
- check out the report from The Star-Ledger
- read the article from PharmaTimes

Related Articles:
BMS pays $505M for Adnexus. Report
Better times ahead for BMS? Report
Cornelius get big payday for BMS temp job. Report

Read more on: Bristol-Myers Squibb